Your browser is no longer supported. Please, upgrade your browser.
VVUS VIVUS, Inc. daily Stock Chart
Index- P/E- EPS (ttm)-2.70 Insider Own7.09% Shs Outstand17.87M Perf Week-5.12%
Market Cap14.44M Forward P/E- EPS next Y-1.64 Insider Trans0.00% Shs Float14.82M Perf Month-26.85%
Income-28.80M PEG- EPS next Q-0.55 Inst Own7.50% Short Float3.45% Perf Quarter-41.04%
Sales73.20M P/S0.20 EPS this Y14.90% Inst Trans-18.00% Short Ratio0.65 Perf Half Y-70.52%
Book/sh-6.94 P/B- EPS next Y15.50% ROA-12.20% Target Price- Perf Year-79.53%
Cash/sh- P/C- EPS next 5Y0.80% ROE44.40% 52W Range0.78 - 4.75 Perf YTD-70.96%
Dividend- P/FCF- EPS past 5Y18.00% ROI-6.40% 52W High-83.37% Beta-0.84
Dividend %- Quick Ratio0.30 Sales past 5Y-9.40% Gross Margin78.20% 52W Low1.28% ATR0.09
Employees59 Current Ratio0.40 Sales Q/Q21.70% Oper. Margin-12.10% RSI (14)29.98 Volatility7.06% 8.37%
OptionableYes Debt/Eq- EPS Q/Q34.50% Profit Margin-39.30% Rel Volume1.12 Prev Close0.81
ShortableNo LT Debt/Eq- EarningsMay 06 AMC Payout- Avg Volume788.90K Price0.79
Recom- SMA20-24.35% SMA50-29.85% SMA200-64.92% Volume880,519 Change-2.47%
May-04-16Downgrade WallachBeth Buy → Hold
Nov-05-15Upgrade WallachBeth Hold → Buy $2.30 → $2.80
Jul-31-15Reiterated RBC Capital Mkts Outperform $6 → $4
Jan-23-15Initiated RBC Capital Mkts Outperform $6
Feb-25-14Reiterated WallachBeth Hold $11 → $8
Nov-15-13Initiated WallachBeth Hold $11
Oct-03-13Upgrade Cowen Hold → Outperform $19
Jul-19-13Downgrade Needham Buy → Hold
Jan-18-13Reiterated MLV & Co Buy $40 → $21
Sep-24-12Reiterated Needham Buy $38 → $32
Jul-19-12Reiterated MLV & Co Buy $34 → $40
Jul-18-12Reiterated Rodman & Renshaw Mkt Outperform $39 → $52
Jul-18-12Downgrade Brean Murray Buy → Hold
Apr-30-12Reiterated MLV & Co Buy $30 → $34
Feb-23-12Upgrade Rodman & Renshaw Mkt Perform → Mkt Outperform $39
Feb-23-12Upgrade Brean Murray Sell → Hold $2
Feb-23-12Reiterated MLV & Co Buy $22 → $30
Feb-23-12Reiterated JMP Securities Mkt Outperform $16 → $45
Jan-17-12Reiterated MLV & Co Buy $16 → $22
Jan-05-12Initiated Rodman & Renshaw Mkt Perform
Jun-10-20 06:00AM  
Jun-02-20 07:30AM  
May-22-20 10:21PM  
May-08-20 06:05AM  
May-06-20 04:05PM  
May-01-20 08:40AM  
Apr-03-20 03:00PM  
Apr-01-20 09:02AM  
Mar-31-20 07:30AM  
Mar-12-20 08:25PM  
Mar-05-20 11:20AM  
Mar-03-20 04:05PM  
Mar-02-20 07:30AM  
Feb-19-20 07:30AM  
Feb-18-20 07:30AM  
Feb-05-20 07:30AM  
Feb-03-20 10:10AM  
Jan-07-20 07:30AM  
Jan-02-20 07:30AM  
Dec-31-19 07:30AM  
Dec-24-19 12:57PM  
Dec-18-19 07:30AM  
Nov-25-19 07:30AM  
Nov-20-19 09:37AM  
Nov-15-19 12:28AM  
Nov-11-19 04:45AM  
Nov-05-19 04:05PM  
Oct-28-19 07:30AM  
Oct-22-19 07:30AM  
Oct-21-19 07:30AM  
Oct-07-19 01:45PM  
Oct-04-19 01:43PM  
Oct-03-19 07:30AM  
Aug-28-19 07:30AM  
Aug-27-19 07:30AM  
Aug-23-19 11:30AM  
Aug-21-19 12:15PM  
Aug-20-19 07:30AM  
Aug-13-19 12:36PM  
Aug-08-19 11:18AM  
Aug-06-19 04:05PM  
Aug-05-19 07:30AM  
Jul-23-19 07:30AM  
Jun-26-19 04:05PM  
Jun-14-19 12:16PM  
Jun-11-19 07:30AM  
May-31-19 10:00AM  
May-28-19 07:30AM  
May-15-19 07:53AM  
May-06-19 10:00AM  
May-04-19 03:05AM  
Apr-30-19 06:27PM  
Apr-29-19 07:24AM  
Apr-16-19 07:30AM  
Mar-14-19 07:30AM  
Feb-28-19 08:47PM  
Feb-26-19 04:05PM  
Feb-13-19 07:30AM  
Feb-05-19 03:02PM  
Feb-04-19 04:00PM  
Jan-15-19 07:55AM  
Jan-14-19 07:30AM  
Jan-03-19 03:29PM  
Dec-27-18 07:30AM  
Dec-25-18 12:28PM  
Dec-14-18 07:59AM  
Dec-13-18 07:56AM  
Dec-01-18 09:31AM  
Nov-15-18 08:25AM  
Nov-07-18 07:16AM  
Nov-02-18 11:31AM  
Nov-01-18 07:36PM  
Oct-29-18 07:30AM  
Oct-26-18 07:30AM  
Oct-10-18 07:30AM  
Sep-26-18 07:30AM  
Sep-24-18 07:30AM  
Sep-21-18 07:30AM  
Sep-11-18 10:57AM  
Sep-10-18 07:30AM  
Sep-06-18 11:31AM  
Aug-27-18 07:30AM  
Aug-22-18 09:07AM  
Aug-21-18 09:40AM  
Aug-08-18 10:14AM  
Aug-07-18 07:03PM  
Aug-06-18 07:30AM  
Jul-31-18 07:30AM  
VIVUS, Inc. operates as a specialty pharmaceutical company primarily in the United States and the European Union. The company offers Qsymia for the treatment of obesity as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body-mass index of 30 or greater (obese patients) or 27 or greater (overweight patients) in the presence of at least one weight-related comorbidity, such as hypertension, type 2 diabetes mellitus, or high cholesterol. It also provides PANCREAZE to treat exocrine pancreatic insufficiency due to cystic fibrosis, chronic pancreatitis, pancreatic cancer or other conditions; and STENDRA/SPEDRA, an oral phosphodiesterase type 5 inhibitor for erectile dysfunction. In addition, the company is developing Qsymia, which has completed Phase II clinical study for treating various diseases, including obstructive sleep apnea, diabetes, nonalcoholic steatohepatitis, and bariatric surgery; and VI-0106 that has completed Phase IIa study to treat patients with pulmonary arterial hypertension. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation; Menarini Group; Sanofi; Metuchen Pharmaceuticals, LLC; Selten Pharma, Inc.; and Alvogen Malta Operations (ROW) Ltd. VIVUS, Inc. was founded in 1991 and is headquartered in Campbell, California.